Premium
Clinical study of hereditary ovarian cancer syndrome in Shandong province, East China
Author(s) -
Sheng Xiugui,
Zhong Yan,
Lu Chunhua,
Peng Jingwei,
Yu Hao,
Guo Jing
Publication year - 2018
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.12447
Subject(s) - medicine , ovarian cancer , china , gynecology , cancer , political science , law
Objective To explore the clinicopathologic characteristics and prognosis of hereditary ovarian cancer syndrome ( HOCS ) in Shandong province, East China. Methods The present retrospective study assessed the clinicopathologic characteristics and prognosis among patients with HOCS treated at Shandong Cancer Hospital, China, between January 1, 2008, and January 31, 2016. Data from women with primary ovarian cancer who met HOCS diagnostic criteria (genetic‐disease group) were compared with data from a control group of 100 women with sporadic ovarian cancer (sporadic‐disease group) identified using simple random sampling. Results Among 1247 records of primary ovarian cancer during the study period, 96 (7.7%) women from 77 pedigrees had HOCS (genetic‐disease group), and 65 of these pedigrees had sufficient data available for inclusion. In the genetic‐disease group, 55 (85%) and 10 (15%) women inherited the disease through the maternal and paternal lines, respectively. Age of onset was earlier in the genetic‐disease group compared with the sporadic‐disease group ( P =0.016), the proportion of mucinous adenocarcinoma was lower in the genetic‐disease group ( P =0.006), and the genetic‐disease group had higher 3‐year ( P =0.036) and 5‐year ( P =0.035) survival rates. Conclusion HOCS exhibited maternal lineage primarily, and featured an early age of onset, advanced disease (stage III ), serous adenocarcinoma, and a better prognosis after comprehensive treatment (including surgery, chemotherapy, and occasionally radiotherapy) relative to sporadic ovarian cancer.